PERSPECTIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 99.00% for the 9-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2022-11-14
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-09-30 was 99.00%, a 19.28% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-09-30 was 83.00%.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2015 was 107.00%.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2012 was 132.47%, a 1.87% increase from fiscal 2011.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2011 was 130.04%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | 99.00% 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | 99.00% 10-Q · filed 2022-02-09 | ||||
| 2021-09-30 | 99.00% 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | 83.00% 10-Q · filed 2022-02-09 | ||||
| 2020-09-30 | 83.00% 10-Q · filed 2021-11-10 | ||||
| 2015-06-30 | 107.00% 10-K · filed 2017-09-28 | ||||
| 2013-09-06 | 132.31% 10-Q · filed 2015-05-15 | ||||
| 2013-09-05 | 132.31% 10-Q · filed 2015-05-15 | ||||
| 2012-06-30 | 132.47% 10-K · filed 2013-09-30 | ||||
| 2011-06-30 | 130.04% 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |